eli lilly tirzepatide direct Lilly, Maker of Mounjaro and Zepbound, Wades Into Telehealth Ro, Eli Lilly strike deal

GLP-1 Pathway Shared with Ozempic Reduces appetite via hypothalamic signaling Slows gastric emptying (delays food leaving stomach) Stimulates glucose-dependent insulin secretion Suppresses glucagon release (reduces liver glucose output) Improves satiety and reduces food intake GIP Pathway Unique to Mounjaro Enhances insulin sensitivity in adipose tissue Improves fat metabolism and lipid handling Reduces fat storage in visceral depots Boosts energy expenditure (thermogenesis) Synergizes with GLP-1 for amplified weight loss Combined Effects on the Body Clinical Evidence SURMOUNT Clinical Trial Results Tirzepatide has the strongest evidence base of any weight loss medication ever studied

Different receptors

2.6 Statistical analysis Data analysis was conducted with GraphPad Prism software, version 9.5.1

Retatrutide takes that concept a step further by introducing glucagon receptor activity, allowing researchers to investigate an even broader network of hormonal signaling